Global Japanese Encephalitis Vaccines Market - 2024-2031

Global Japanese Encephalitis Vaccines Market - 2024-2031

Global Japanese Encephalitis (JE) Vaccines Market reached US$ XX million in 2023 and is expected to reach US$ XX million by 2031, growing with a CAGR of XX % during the forecast period 2024-2031.

Japanese encephalitis (JE) vaccines are vaccines that provide immunity against Japanese encephalitis virus (JEV), which is a mosquito-borne virus that can cause inflammation of the brain. Japanese encephalitis is primarily found in rural areas of Asia and the Western Pacific, with the highest incidence in rural parts of Southeast Asia and the Far East.

JE vaccines are integrated into national immunization programs in endemic countries where the disease burden is significant. Governments and public health authorities prioritize vaccination efforts as part of broader strategies to reduce the incidence of Japanese encephalitis and its impact on public health. Addressing Japanese encephalitis aligns with global health security initiatives aimed at preventing, detecting, and responding to infectious disease threats. Strengthening vaccination programs and disease surveillance capacities contribute to overall efforts to mitigate the spread of emerging infectious diseases.

Market Dynamics: Drivers and Restraints

Increasing incidence of Japanese Encephalitis

The prevalence of Japanese Encephalitis virus (JEV) in endemic regions, particularly in Asia and the Western Pacific, drives the demand for JE vaccines. The high incidence of JE cases, especially during peak transmission seasons, underscores the importance of vaccination as a preventive measure. The surge in JE cases often prompts concerns among travelers visiting endemic regions.

Tourists, business travelers, and expatriates become more vigilant about potential health risks, including mosquito-borne diseases like JE. Travel medicine practitioners and travel advisory services emphasize the importance of JE vaccination for individuals traveling to affected areas, thereby driving demand for vaccines.

Also, the rising prevalence of diseases helps to accelerates the market growth. For instance, according to an article published in National Library of Medicine 2022, estimated that, there are between 30,000 and 50,000 global cases of Japanese encephalitis each year. Severe disease is estimated to occur in about one in 250 infections. Additionally, European Centre for Disease Prevention and Control (ECDC), estimated that, the overall global incidence of Japanese encephalitis is unknown, but estimates suggest that there are approximately 14 000 to 20 000 fatal cases of acute illness per year.

Market Dynamics: Restraint

High cost associated with the vaccines

High vaccine prices can pose challenges for low-income countries with limited healthcare budgets. These countries may struggle to afford the cost of JE vaccines for inclusion in national immunization programs, leading to limited accessibility for populations at risk. For instance, in countries with high JE burden such as India, affordability issues have historically hindered widespread vaccination coverage.

When JE vaccines are prohibitively expensive, vaccine coverage rates may suffer, leading to suboptimal protection against Japanese encephalitis. Individuals and communities may forego vaccination due to cost concerns, resulting in gaps in immunization coverage and leaving vulnerable populations at risk of infection.

For more details of the report, Request for sample

Segment Analysis

The global japanese encephalitis vaccines market is segmented based on vaccine type, distribution channel and region.

The live-attenuated vaccines from the vaccine type segment accounted for approximately 62.3% of share

The rise of the live-attenuated vaccines segment for Japanese Encephalitis (JE) vaccines market can be attributed to several factors, including efficacy, ease of administration, and potential cost-effectiveness. Live-attenuated vaccines offer certain advantages over other types of vaccines, contributing to their increasing popularity.

For instance, the live-attenuated SA 14-14-2 vaccine has been widely used in China as part of the national immunization program since the late 1980s. This vaccine has demonstrated high efficacy and safety profiles in multiple studies and has been instrumental in reducing the burden of Japanese encephalitis in China. The successful implementation of the SA 14-14-2 vaccine in China has contributed significantly to the rise of the live-attenuated vaccines segment in the JE vaccines market.

Additionally, ease of administration and potential cost-effectiveness of live-attenuated vaccines make them attractive options for rapid deployment in emergency situations. Governments and international organizations often rely on live-attenuated vaccines for mass vaccination campaigns, further driving the growth of this segment in the JE vaccines market.

Geographical Analysis

Asia Pacific accounted for approximately 20.16% of the market share in 2022

The Asia Pacific region accounts for the majority of Japanese encephalitis cases globally, with countries such as India, China, Bangladesh, and Indonesia experiencing high disease burden. The prevalence of JE in these countries drives the demand for vaccines as a preventive measure against the disease.

For instance, according to Indian Journal of Medical Research 2022, estimated that, approximately 67,900 cases are reported every year. The case fatality rate is approximately 25%, and approximately 50 per cent of the cases reportedly suffer from permanent neuropsychiatric dysfunction. Additionally, many countries in the Asia Pacific region have implemented government-led immunization programs to control Japanese encephalitis. These programs aim to vaccinate vulnerable populations, particularly children, through routine immunization schedules.

For instance, countries like China, India, and Thailand have incorporated JE vaccination into their national immunization programs, contributing to increased vaccine uptake in the region. Governments and healthcare authorities have prioritized expanding vaccine coverage to reach underserved populations, including those in rural and remote areas. As a result, more individuals in the region have access to JE vaccination, driving market growth.

COVID-19 Impact Analysis

Many healthcare systems and public health agencies redirected their resources and attention towards combating COVID-19, leading to a temporary diversion of resources away from routine immunization programs, including those for JE vaccines. This redirection of resources may have impacted the implementation of vaccination campaigns and routine immunization schedules for Japanese encephalitis.

COVID-19-related restrictions, such as lockdowns, travel restrictions, and social distancing measures, posed challenges to the delivery of immunization services, including JE vaccination. Healthcare facilities faced disruptions in vaccine delivery, reduced clinic hours, and changes in vaccination protocols to minimize the risk of COVID-19 transmission. These disruptions could have affected vaccine coverage rates for JE and other vaccine-preventable diseases.

Market Segmentation

By Vaccine Type
• Live-attenuated vaccines
• Inactivated vaccines
• Others

By Distribution Channel
• Hospitals
• Retail
• Online

By Region
• North America
U.S.
Canada
Mexico
• Europe
Germany
UK
France
Italy
Spain
Rest of Europe
• South America
Brazil
Argentina
Rest of South America
• Asia-Pacific
China
India
Japan
South Korea
Rest of Asia-Pacific
• Middle East and Africa

Competitive Landscape

The major global players in the market include Bharat Biotech International Limited, Valneva Austria GmbH, Sanofi, Meiji Holdings Co., Ltd., Biological E. Limited, Chengdu Institute of Biological Products Co., Ltd., Takeda Pharmaceutical Company Limited among others.

Why Purchase the Report??
• To visualize the global japanese encephalitis vaccines market segmentation based on vaccine type, distribution channel and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of japanese encephalitis vaccines market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global japanese encephalitis vaccines market report would provide approximately 69 tables, 58 figures and 187 Pages.

Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies